Professor Emeritus, Department of Internal Medicine
To see if Ken Yomer Yoneda is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Pulmonary and Critical Care
I firmly believe that my patients, particularly those with cancer, are best managed with a multidisciplinary team approach and that patients, along with their family members, are integral to the decision-making process. I feel extremely fortunate to be a part of our National Cancer Institute-Designated Comprehensive Cancer Center, and to work alongside the dedicated physicians, nurses and other affiliated personnel who make it possible for our patients to have some of the very best care available anywhere in the world. In addition to offering state-of-the-art care and clinical research trials, we have the unique opportunity to discuss patients with lung cancer and other thoracic malignancies before an expert panel of sub-specialists at our "Thoracic Tumor Board." Whether it is to diagnose, treat or palliate lung cancer, it is through our tumor board, or through close consultation with my medical oncology, thoracic surgery, radiation oncology, and thoracic radiology colleagues, that I am able to devise the best strategies for my patients. I know care must be individualized, as no single strategy works for all patients. Perhaps more so than for any other disease, a cancer patient's overall condition, as well as their desires and expectations, play the most important role in this decision-making process.
As an Interventional Pulmonologist, I also care for patients with non-malignant pulmonary disorders including severe persistent asthma, chronic obstructive pulmonary disease (COPD), non-malignant pleural effusions and benign airway strictures that may require advanced diagnostic or therapeutic procedures, normally offered only at tertiary centers such as UC Davis. Again, I feel honored to work with a dedicated group of Interventional Pulmonologists and a highly skilled and compassionate group of nurses and respiratory therapists in our Interventional Pulmonology Laboratory.
Dr. Yoneda specializes is a General Pulmonology and Interventional Pulmonology Consultant practicing predominantly in the Hospital setting at UCDMC. He has special expertise in advanced invasive Pulmonolgy procedures including Robotic Navigation Bronchoscopy, Endobronchial Ultrasound (EBUS), Bronchoscopic Lung Volume Reduction for Emphysema, treatment of benign and malignant airway disease (utilizing rigid and flexible bronchoscopy, laser, cryotherapy, argon plasma coagulation, electrocautery, airway stenting and dilation) and advanced pleural and bronchoscopic treatment of air leaks and bronchopleural fistulas.
Dr. Yoneda has extensive clinical trials research including active trials utilizing advanced bronchoscopic procedures to treat emphysema/COPD.
B.S., UC Davis, Davis CA 1978
M.D., Northwestern University School of Medicine, Chicago IL 1985
Internal Medicine, University of Kansas Medical Center, Kansas City KS 1985-1986
Internal Medicine, University of Kansas Medical Center, Kansas City KS 1986-1988
Pulmonary and Critical Care, UC Davis Medical Center, Sacramento CA 1993-1996
Outstanding Clinician Award, UC Davis School of Medicine, Department of Internal Medicine, 2016
Division of Pulmonary, Critical Care and Sleep Medicine Fellows Faculty Award, 2015
Shifa Clinic Physician of Excellence Award for Teaching and Clinical Services at a volunteer, UC, 2002, 2003
Best abstract submitted by a fellow in own subspecialty, American Federation for Clinical Research, 1996
B.S. with honors in Biochemistry, UC Davis, 1978
Dransfield MT, Garner JL, Bhatt SP, Slebos DJ, Klooster K, Sciurba FC, Shah PL, Marchetti NT, Sue RD, Wright S, Rivas-Perez H, Wiese TA, Wahidi MM, Goulart de Oliveira H, Armstrong B, Radhakrishnan S, Shargill NS, Criner GJ; LIBERATE Study Group:. Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. Ann Am Thorac Soc. 2020 Jul;17(7):829-838. doi:10.1513/AnnalsATS.201909-666OC. PMID:32223724.
Yoneda KY, Li S, Herth F, Spangler T, Gelfand M, Raina S, Panescu D. Early Preclinical Experience with a Novel Endobronchial Radiofrequency Ablation System for Lung Cancer Treatment. Annu Int Conf IEEE Eng Med Biol Soc. 2019 Jul;2019:174-180. doi:10.1109/EMBC.2019.8857593. PMID:31945872.
Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res. 2019 Jun;8(3):286-301. doi:10.21037/tlcr.2019.04.14. PMID:31367542.
Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, Yang K, Lee J, Nyugen A, Yoneda KY, Lam KS, Li T. High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer. J Hematol Oncol. 2019 Jun 10;12(1):56. doi:10.1186/s13045-019-0740-7. Erratum in: J Hematol Oncol. 2019 Jul 26;12(1):83. PMID:31182116.
Gong J, Gregg JP, Ma W, Yoneda K, Moore EH, Daly ME, Zhang Y, Williams MJ, Li T. Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors. J Natl Compr Canc Netw. 2019 Apr 1;17(4):297-301. doi:10.6004/jnccn.2019.7291. PMID:30959466.
Liao SY, Linderholm AL, Yoneda KY, Kenyon NJ, Harper RW. Airway transcriptomic profiling after bronchial thermoplasty. ERJ Open Res. 2019 Feb 18;5(1):00123-2018. doi:10.1183/23120541.00123-2018. PMID:30792984.
Tan LD, Yoneda KY, Louie S, Hogarth DK, Castro M. Bronchial Thermoplasty: A Decade of Experience: State of the Art. J Allergy Clin Immunol Pract. 2019 Jan;7(1):71-80. doi:10.1016/j.jaip.2018.08.017. Epub 2018 Sep 5. PMID:30193939.
Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, Sciurba FC, Shah PL, Wahidi MM, de Oliveira HG, Morrissey B, Cardoso PFG, Hays S, Majid A, Pastis N Jr, Kopas L, Vollenweider M, McFadden PM, Machuzak M, Hsia DW, Sung A, Jarad N, Kornaszewska M, Hazelrigg S, Krishna G, Armstrong B, Shargill NS, Slebos DJ; LIBERATE Study Group. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018 Nov 1;198(9):1151-1164. doi:10.1164/rccm.201803-0590OC. PMID:29787288.
Yoneda KY, Scranton JR, Cadogan MA, Tassell V, Nadanaciva S, Wilner KD, Stollenwerk NS. Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials. Clin Lung Cancer. 2017 Sep;18(5):472-479. doi:10.1016/j.cllc.2017.03.004. Epub 2017 Mar 14. PMID:28373069.
Tan LD, Kenyon N, Yoneda KY, Louie S. Bronchial thermoplasty: implementing best practice in the era of cost containment. J Asthma Allergy. 2017 Jul 26;10:225-230. doi:10.2147/JAA.S135291. PMID:28794646.